Comparison of various drugs in development of combination therapy with... | Download Table
LAMA/LABA therapy reduced risk for COPD exacerbation, pneumonia hospitalization
GSK 렐바 엘립타 시장 점유율 40% 돌파 < 제약산업 < 제약·유통 < 기사본문 - 의학신문
GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment
Lama/Laba-Therapie bei COPD: Eine bedeutende Rolle
GSK's Anoro first LAMA/LABA approved for COPD in US - PMLiVE
MEDI:GATE NEWS : GSK 트렐리지 엘립타, 성인 천식 환자 위한 3제 복합요법 치료제로 적응증 확대
LAMA/LABA, '계열 이팩트' 인정 시기상조 < 제약·바이오 < 산업 < 기사본문 - 팜뉴스
Population-based study of LAMA monotherapy effectiveness compared with LABA/ LAMA as initial treatment for COPD in primary care | npj Primary Care Respiratory Medicine
GSK 아노로 엘립타, LAMA/LABA 복합제 간 직접 비교 연구 결과, 대조군 대비 우월한 폐기능 개선 효과 입증
베링거표 LAMA+LABA COPD 복합제 국내 상륙 임박
Toby Capstick on X: "#Trelegy Ellipta: The second ICS/LAMA/LABA inhaler in the UK, licensed for #COPD. https://t.co/NSYtv7bTYS (An alternative ICS/LABA /LAMA inhaler is available: #Trimbow MDI) https://t.co/vQBgh9lvM2" / X
How Will The New GSK Respiratory Portfolio Fare In 2017? (NYSE:GSK) | Seeking Alpha
Wirkstoffkombination für COPD-Patienten: Erstattungsbetrag für Anoro vereinbart
베링거, 1일 1회 'LAMA+LABA' COPD 복합제 합류
Il ruolo dei LABA/LAMA nel setting del MMG
GSKpro GR | Προϊοντική ενημέρωση για Επαγγελματίες Υγείας
GESTIONE DELLA BPCO E DELL'ASMA: NOVITÀ TERAPEUTICHE E SOSTENIBILITÀ
Trelegy - a new drug from GSK | X7 Research
Anoro Ellipta Full Prescribing Information, Dosage & Side Effects | MIMS Philippines
Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study | Archivos de Bronconeumología
Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management | npj Primary Care Respiratory Medicine
CAPTAIN: Effects of baseline SABA use on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA | GSK
Presentazione di PowerPoint
BPCO, rimborsabile la triplice terapia fluticasone furoato/umeclidinio/vilanterolo
